Advertisement
AJOG Home
Advanced SearchSave search
SMFM debate| Volume 205, ISSUE 4, P296-297, October 01, 2011

Magnesium sulfate for fetal neuroprotection

DOI:https://doi.org/10.1016/j.ajog.2011.02.083
Magnesium sulfate for fetal neuroprotection
Previous ArticleMagnesium sulfate for neuroprotection: now or not yet
Next ArticleMagnesium sulfate for neuroprotection in patients at risk for early preterm delivery: not yet
      In the 3 large, well-done randomized placebo-controlled trials, antenatal magnesium sulfate (MgSO4) reduced the risk of cerebral palsy among children who survived early preterm birth. Crowther and colleagues
      • Crowther C.A.
      • Hiller J.E.
      • Doyle L.W.
      • Haslam R.R.
      Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
      JAMA. 2003; 290: 2669-2676
      studied 1062 women. Moderate or severe cerebral palsy (inability to walk unaided) was significantly less frequent among children in the MgSO4 group, 3.4% vs 6.6%. In the National Institutes of Health Maternal-Fetal Medicine Units Network trial (the BEAM trial) 2241 women were enrolled.
      • Rouse D.J.
      • Hirtz D.G.
      • Thom E.
      • et al.
      A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
      N Engl J Med. 2008; 359: 895-905
      As in the trial of Crowther et al,
      • Crowther C.A.
      • Hiller J.E.
      • Doyle L.W.
      • Haslam R.R.
      Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
      JAMA. 2003; 290: 2669-2676
      MgSO4 significantly reduced the risk of moderate to severe cerebral palsy, 1.9% vs 3.5%. Among the offspring of women randomized <28 weeks, the respective risks were 2.7% and 6.1%. Marret et al
      • Marret S.
      • Maroeau L.
      • Follet-Bouhamed C.
      • et al.
      Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREAMAG trial.
      Gynecol Obstet Fertil. 2008; 36: 278-288
      studied 573 mothers: MgSO4 lowered the risk of cerebral palsy, 7.0% vs 10.2%. These 3 trials and 2 more (6145 children) are included in a Cochrane Systematic Review that concluded that MgSO4 reduced the risk of cerebral palsy by 32% but had no effect on fetal or infant mortality.
      • Doyle L.W.
      • Crowther C.A.
      • Middleton P.
      • Marret S.
      • Rouse D.
      Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.
      Cochrane Database Syst Rev. 2009; 1 (CD004661)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Crowther C.A.
        • Hiller J.E.
        • Doyle L.W.
        • Haslam R.R.
        Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
        JAMA. 2003; 290: 2669-2676
        View in Article
        • Rouse D.J.
        • Hirtz D.G.
        • Thom E.
        • et al.
        A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
        N Engl J Med. 2008; 359: 895-905
        View in Article
        • Marret S.
        • Maroeau L.
        • Follet-Bouhamed C.
        • et al.
        Effect of magnesium sulphate on mortality and neurologic morbidity of the very preterm newborn with two-year neurological outcome: results of the prospective PREAMAG trial.
        Gynecol Obstet Fertil. 2008; 36: 278-288
        View in Article
        • Doyle L.W.
        • Crowther C.A.
        • Middleton P.
        • Marret S.
        • Rouse D.
        Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.
        Cochrane Database Syst Rev. 2009; 1 (CD004661)
        View in Article

      Article Info

      Identification

      DOI: https://doi.org/10.1016/j.ajog.2011.02.083

      Copyright

      © 2011 Mosby, Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX